These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

9177 related items for PubMed ID: 18773755

  • 1. [Pharmacological therapy of obesity].
    Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
    Van Gaal L, Pi-Sunyer X, Després JP, McCarthy C, Scheen A.
    Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
    [Abstract] [Full Text] [Related]

  • 3. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A, Jeitler K, Horvath K, Berghold A, Posch N, Meschik J, Semlitsch T.
    Cochrane Database Syst Rev; 2016 Mar 02; 3():CD007654. PubMed ID: 26934640
    [Abstract] [Full Text] [Related]

  • 4. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
    Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group.
    JAMA; 2006 Feb 15; 295(7):761-75. PubMed ID: 16478899
    [Abstract] [Full Text] [Related]

  • 5. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
    Scheen AJ.
    J Neuroendocrinol; 2008 May 15; 20 Suppl 1():139-46. PubMed ID: 18426513
    [Abstract] [Full Text] [Related]

  • 6. Drug treatments for obesity: orlistat, sibutramine, and rimonabant.
    Padwal RS, Majumdar SR.
    Lancet; 2007 Jan 06; 369(9555):71-7. PubMed ID: 17208644
    [Abstract] [Full Text] [Related]

  • 7. [Pharmacotherapy in the treatment of obesity].
    Hamann A.
    MMW Fortschr Med; 2006 Mar 02; 148(9):36-8. PubMed ID: 16566392
    [Abstract] [Full Text] [Related]

  • 8. Effect of antiobesity medications in patients with type 2 diabetes mellitus.
    Choussein S, Makri AA, Frangos CC, Petridou ET, Daskalopoulou SS.
    Diabetes Obes Metab; 2009 Jul 02; 11(7):641-64. PubMed ID: 19236442
    [Abstract] [Full Text] [Related]

  • 9. Rimonabant for the treatment of overweight and obese people.
    Burch J, McKenna C, Palmer S, Norman G, Glanville J, Sculpher M, Woolacott N.
    Health Technol Assess; 2009 Oct 02; 13 Suppl 3():13-22. PubMed ID: 19846024
    [Abstract] [Full Text] [Related]

  • 10. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.
    Ara R, Blake L, Gray L, Hernández M, Crowther M, Dunkley A, Warren F, Jackson R, Rees A, Stevenson M, Abrams K, Cooper N, Davies M, Khunti K, Sutton A.
    Health Technol Assess; 2012 Oct 02; 16(5):iii-xiv, 1-195. PubMed ID: 22340890
    [Abstract] [Full Text] [Related]

  • 11. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.
    Diabetes Nutr Metab; 2004 Aug 02; 17(4):222-9. PubMed ID: 15575343
    [Abstract] [Full Text] [Related]

  • 12. Long-term pharmacotherapy for obesity and overweight.
    Padwal R, Li SK, Lau DC.
    Cochrane Database Syst Rev; 2003 Aug 02; (4):CD004094. PubMed ID: 14584004
    [Abstract] [Full Text] [Related]

  • 13. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
    Després JP, Golay A, Sjöström L, Rimonabant in Obesity-Lipids Study Group.
    N Engl J Med; 2005 Nov 17; 353(20):2121-34. PubMed ID: 16291982
    [Abstract] [Full Text] [Related]

  • 14. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
    Scheen AJ, Ernest P.
    Diabetes Metab; 2002 Dec 17; 28(6 Pt 1):437-45. PubMed ID: 12522323
    [Abstract] [Full Text] [Related]

  • 15. Modern medical management of obesity: the role of pharmaceutical intervention.
    Aronne LJ.
    J Am Diet Assoc; 1998 Oct 17; 98(10 Suppl 2):S23-6. PubMed ID: 9787732
    [Abstract] [Full Text] [Related]

  • 16. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A, Winterholer S, Jeitler K, Horvath K, Berghold A, Krenn C, Semlitsch T.
    Cochrane Database Syst Rev; 2021 Jan 17; 1(1):CD007654. PubMed ID: 33454957
    [Abstract] [Full Text] [Related]

  • 17. [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
    Scheen AJ, Van Gaal LG, Després JP, Pi-Sunyer X, Golay A, Hanotin C.
    Rev Med Suisse; 2006 Aug 23; 2(76):1916-23. PubMed ID: 16972542
    [Abstract] [Full Text] [Related]

  • 18. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.
    Johansson K, Neovius K, DeSantis SM, Rössner S, Neovius M.
    Obes Rev; 2009 Sep 23; 10(5):564-75. PubMed ID: 19460116
    [Abstract] [Full Text] [Related]

  • 19. Long-term pharmacotherapy for obesity and overweight.
    Padwal R, Li SK, Lau DC.
    Cochrane Database Syst Rev; 2004 Sep 23; 2003(3):CD004094. PubMed ID: 15266516
    [Abstract] [Full Text] [Related]

  • 20. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A.
    Clin Ther; 2004 Sep 23; 26(9):1427-35. PubMed ID: 15531005
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 459.